Onkológia 2/2019
Management of adverse reactions in treatment with mTOR and CDK4/6 inhibitors
mTOR inhibitors and CDK4/6 inhibitors share common prescription usage – metastatic, hormone-receptor positive, HER-2 negative breast cancer. Given the fact of renal cell cancer as another indication for mTOR inhibitors, they are well established among Slovak oncologists and management of their side effects is well known. New compounds are CDK4/6 inhibitors, which are not yet reimbursed from public health budget by Ministry of Health. Given their clinical effectiveness and favorable profile, it is advisable to known management of likely adverse reactions of CDK4/6i.
Keywords: breast cancer, mTOR inhibitors, CDK4/6 inhibitors, adverse reactions












